GPR119
G protein-coupled receptor 119 also known as GPR119 is a G protein-coupled receptor that in humans is encoded by the GPR119 gene.
GPR119, along with GPR55 and GPR18, have been implicated as novel cannabinoid receptors.
Pharmacology
GPR119 is expressed predominantly in the pancreas and gastrointestinal tract in rodents and humans, as well as in the brain in rodents. Activation of the receptor has been shown to cause a reduction in food intake and body weight gain in rats. GPR119 has also been shown to regulate incretin and insulin hormone secretion. As a result, new drugs acting on the receptor have been suggested as novel treatments for obesity and diabetes.Ligands
A number of endogenous, synthetic and plant derived ligands for this receptor have been identified:- 2-Oleoylglycerol
- Anandamide
- AR-231,453
- MBX-2982
- Oleoylethanolamide
- PSN-375,963
- PSN-632,408
Human microbiota and GPR119 activation
The experiment have isolated both the palmitoyl and oleoyl analogs of N-acyl serinol, and found the latter only differs from 2-OG: C21H40O4 by the presence of an amide instead of an ester, and from OEA: C20H39NO2 by the presence of an additional ethanol substituent, where the N-oleoyl serinol, is a similarly potent GPR119 agonist compared to the endogenous ligand OEA, but elicits almost a 2-fold greater maximum activation, do suggest that chemical mimicry of eukaryotic signalling molecules may be common among commensal bacteria, that communicate through interactions between these two fundamental systems—which form the gut microbiota-endocannabinoidome axis.